A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Elevated CK2 activity has been associated with malignant transformation and aggressive tumor
growth. Over expression of CK2 has been documented in multiple types of cancers, including
multiple myeloma, and inhibition of CK2 represents a potential therapeutic strategy to
target a specific molecular defect perpetuating many cancers. CX-4945 has demonstrated
potent inhibition of CK2 enzymatic activity. This study will evaluate the safety,
pharmacokinetics, and pharmacodynamic effects of CX-4945 when administered to patients with
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Adverse events classified as Dose limiting toxicities. Determination of maximum tolerated dose.
One year (assessed at Cycle 1).
United States: Food and Drug Administration
|Cleveland, Ohio 44195|
|Seattle, Washington 98195|
|McLean, Virginia 22101|
|Charleston, South Carolina|
|Oregon Health Science University||Portland, Oregon 97239|